Tibetan sound meditation for cognitive dysfunction: Results of a randomized controlled pilot trial

Psycho-Oncology

Volumn 22, Issue 10, 2013, Pages 2354-2363

  Milbury, K ^a   Chaoul, A ^a   Biegler, K ^b   Wangyal, T ^c   Spelman, A ^a   Meyers, C A ^a   Arun, B ^a   Palmer, J L ^a   Taylor, J ^a   Cohen, L ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Ligmincha Institute   (United States)

Author keywords

breast cancer; chemotherapy; cognitive dysfunction; meditation; mental health; quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; TAMOXIFEN; VENLAFAXINE;

ADULT; AGED; ARTICLE; BREAST CANCER; BRIEF FATIGUE INVENTORY; CANCER CHEMOTHERAPY; CANCER PATIENT; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DIGIT SYMBOL; DISEASE ASSOCIATION; DISEASE SEVERITY; FACT SP; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY COGNITION; HEALTH PROGRAM; HUMAN; MASTECTOMY; MEDITATION; MENTAL HEALTH; NEUROPSYCHOLOGICAL TEST; PARTIAL MASTECTOMY; PITTSBURGH SLEEP QUALITY INDEX; PSYCHOLOGIC TEST; PSYCHOMETRY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELIGION; REY AUDITORY VERBAL LEARNING TEST; SEGMENTAL MASTECTOMY; SELF REPORT; SHORT FORM 36; SHORT TERM MEMORY; SLEEP DISORDER; SYMPTOM; TASK PERFORMANCE; TIBETAN MEDICINE; TIBETAN SOUND MEDITATION; TREATMENT DURATION; TREATMENT OUTCOME; VERBAL MEMORY; BREAST NEOPLASMS; CHEMICALLY INDUCED; COGNITION DISORDERS; FEASIBILITY STUDY; HOSPITAL ADMISSION; MIDDLE AGED; PILOT STUDY; PROCEDURES; PSYCHOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COGNITION DISORDERS; DEPRESSION; FATIGUE; FEASIBILITY STUDIES; FEMALE; HUMANS; MEDITATION; MENTAL HEALTH; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; QUALITY OF LIFE; SPIRITUALITY; TREATMENT OUTCOME; WAITING LISTS;

EID: 84885321259     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.3296     Document Type: Article

References (79)

1. Koppelmans V, Breteler MM, Boogerd W, et al,. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol 2012; 30: 1080-1086.
2. de Ruiter MB, Reneman L, Boogerd W, et al,. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp 2011; 32: 1206-1219.
3. Ahles TA, Saykin AJ, Furstenberg CT, et al,. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20: 485-493.
4. Yamada TH, Denburg NL, Beglinger LJ, Schultz SK,. Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy. J Neuropsychiatry Clin Neurosci 2010; 22: 48-54.
5. Wefel JS, Vardy J, Ahles T, Schagen SB,. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011; 12: 703-708.
6. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA,. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2010; 116: 3348-3356.
7. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB,. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008; 19: 623-629.
8. Schagen SB, van Dam FS, Muller MJ, et al,. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85: 640-650.
9. van Dam FS, Schagen SB, Muller MJ, et al,. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90: 210-218.
10. Downie FP, Mar Fan HG, Houede-Tchen N, Yi Q, Tannock IF,. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology 2006; 15: 921-930.
11. Tchen N, Juffs HG, Downie FP, et al,. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003; 21: 4175-4183.
12. Fan HG, Houede-Tchen N, Yi QL, et al,. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 2005; 23: 8025-8032.
13. Castellon SA, Ganz PA, Bower JE, et al,. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004; 26: 955-969.
14. Tager FA, McKinley PS, Schnabel FR, et al,. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat 2010; 123: 25-34.
15. Weis J, Poppelreuter M, Bartsch HH,. Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: 'subjective' complaints and 'objective' neuropsychological test results. Psychooncology 2009; 18: 775-782.
16. Poppelreuter M, Weis J, Kulz AK, et al,. Cognitive dysfunction and subjective complaints of cancer patients. A cross-sectional study in a cancer rehabilitation centre. Eur J Cancer 2004; 40: 43-49.
17. Poppelreuter M, Weis J, Mumm A, Orth HB, Bartsch HH,. Rehabilitation of therapy-related cognitive deficits in patients after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 79-90.
18. Wefel JS, Schagen SB,. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep 2012; 12: 267-275.
19. Vardy J, Dhillon H,. The fog hasn't lifted on chemobrain yet: ongoing uncertainty regarding the effects of chemotherapy and breast cancer on cognition. Breast Cancer Res Treat 2010; 123: 35-37.
20. Kayl AE, Wefel JS, Meyers CA,. Chemotherapy and cognition: effects, potential mechanisms, and management. Am J Ther 2006; 13: 362-369.
21. NCI. President's cancer panel meeting. Cancer care issues in the United States quality of care, quality of life, January 1, 1997 to December 31, 1998: National Cancer Institute.
22. NCCS (ed). Palliative care and symptom management. Cognitive Issues [cited; Available from: http://www.canceradvocacy. org/resources/essential/ effects/cognitive-test.aspx (accessed February 2007).
23. Gehring K, Roukema JA, Sitskoorn MM,. Review of recent studies on interventions for cognitive deficits in patients with cancer. Expert Rev Anticancer Ther 2012; 12: 255-269.
24. FDA. Drugs@FDA, FDA approved drug products. www.accessdata.fda.gov/ scripts/cder/drugsatfda/index.cfm.
25. Ferguson RJ, McDonald BC, Rocque MA, et al,. Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology 2012; 21: 176-186.
26. Ferguson RJ, Ahles TA, Saykin AJ, et al,. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology 2007; 16: 772-777.
27. McDougall GJ, Becker H, Acee TW, Vaughan PW, Delville CL,. Symptom management of affective and cognitive disturbance with a group of cancer survivors. Arch Psychiatr Nurs 2011; 25: 24-35.
28. Cimprich B,. Development of an intervention to restore attention in cancer patients. Cancer Nurs 1993; 16: 83-92.
29. Crandall C, Petersen L, Ganz PA, Greendale GA,. Association of breast cancer and its therapy with menopause-related symptoms. Menopause 2004; 11: 519-530.
30. Schag CA, Ganz PA, Polinsky ML, et al,. Characteristics of women at risk for psychosocial distress in the year after breast cancer. J Clin Oncol 1993; 11: 783-793.
31. Bower JE, Ganz PA, Irwin MR, et al,. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? J Clin Oncol 2011; 29: 3517-3522.
32. Society AC. Breast Cancer Facts & Figures 2011-2012. Atlanta, 2011.
33. Henson HK,. Breast cancer and sexuality. Sex Disabil 2000; 20: 261-275.
34. Biegler KA, Chaoul MA, Cohen L,. Cancer, cognitive impairment, and meditation. Acta Oncol 2009; 48: 18-26.
35. Oh B, Butow PN, Mullan BA, et al,. Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. Support Care Cancer 2011; 20: 1235-1242.
36. Reid-Arndt SA, Matsuda S, Cox CR,. Tai Chi effects on neuropsychological, emotional, and physical functioning following cancer treatment: a pilot study. Complement Ther Clin Pract 2012; 18: 26-30.
37. Kang DH, Jo HJ, Jung WH, et al,. The effect of meditation on brain structure: cortical thickness mapping and diffusion tensor imaging. Soc Cogn Affect Neurosci 2012; 8: 27-33.
38. Jha AP, Krompinger J, Baime MJ,: Mindfulness training modifies subsystems of attention. Cogn Affect Behav Neurosci 2007; 7: 109-119.
39. Kozasa EH, Sato JR, Lacerda SS, et al,. Meditation training increases brain efficiency in an attention task. Neuroimage 2012; 59: 745-749.
40. Brefczynski-Lewis JA, Lutz A, Schaefer HS, Levinson DB, Davidson RJ,. Neural correlates of attentional expertise in long-term meditation practitioners. Proc Natl Acad Sci U S A 2007; 104: 11483-11488.
41. Slagter HA, Lutz A, Greischar LL, et al,. Mental training affects distribution of limited brain resources. PLoS Biol 2007; 5: e138.
42. Lutz A, Greischar LL, Rawlings NB, Ricard M, Davidson RJ,. Long-term meditators self-induce high-amplitude gamma synchrony during mental practice. Proc Natl Acad Sci U S A 2004; 101: 16369-16373.
43. Lutz A, Slagter HA, Dunne JD, Davidson RJ,. Cognitive-emotional interactions-Attention regulation and monitoring in meditation. Trends Cogn Sci 2008; 12: 163-169.
44. van Leeuwen S, Singer W, Melloni L,. Meditation increases the depth of information processing and improves the allocation of attention in space. Front Hum Neurosci 2012; 6: 133.
45. Davidson RJ, Kabat-Zinn J, Schumacher J, et al,. Alterations in brain and immune function produced by mindfulness meditation. Psychosom Med 2003; 65: 564-570.
46. Witek-Janusek L, Albuquerque K, Chroniak KR, et al,. Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer. Brain Behav Immun 2008; 22: 969-981.
47. Ahles TA, Saykin AJ,. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007; 7: 192-201.
48. Kabat-Zinn J,. An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: theoretical considerations and preliminary results. Gen Hosp Psychiatry 1982; 4: 33-47.
49. Ludwig DS, Kabat-Zinn J,. Mindfulness in medicine. JAMA 2008; 300: 1350-1352.
50. Kwekkeboom KL, Cherwin CH, Lee JW, Wanta B,. Mind-body treatments for the pain-fatigue-sleep disturbance symptom cluster in persons with cancer. J Pain Symptom Manage 2010; 39: 126-138.
51. Lengacher CA, Reich RR, Post-White J, et al,. Mindfulness based stress reduction in post-treatment breast cancer patients: an examination of symptoms and symptom clusters. J Behav Med 2012; 35: 86-94.
52. Carlson LE, Speca M, Patel KD, Goodey E,. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. Psychosom Med 2003; 65: 571-581.
53. Carlson LE, Ursuliak Z, Goodey E, Angen M, Speca M,. The effects of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients: 6-month follow-up. Support Care Cancer 2001; 9: 112-123.
54. Cohen L, Warneke C, Fouladi RT, Rodriguez MA, Chaoul-Reich A,. Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma. Cancer 2004; 100: 2253-2260.
55. Ospina MB, Bond K, Karkhaneh M, et al,. Clinical trials of meditation practices in health care: characteristics and quality. J Altern Complement Med 2008; 14: 1199-1213.
56. Matchim Y, Armer JM, Stewart BR,. Effects of mindfulness-based stress reduction (MBSR) on health among breast cancer survivors. West J Nurs Res 2011; 33: 996-1016.
57. Lengacher CA, Johnson-Mallard V, Post-White J, et al,. Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer. Psychooncology 2009; 18: 1261-1272.
58. Ando M, Morita T, Akechi T, et al,. The efficacy of mindfulness-based meditation therapy on anxiety, depression, and spirituality in Japanese patients with cancer. J Palliat Med 2009; 12: 1091-1094.
59. Speca M, Carlson LE, Goodey E, Angen M,. A randomized, wait-list controlled clinical trial: the effect of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients. Psychosom Med 2000; 62: 613-622.
60. Hoffman CJ, Ersser SJ, Hopkinson JB, et al,. Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III Breast Cancer: a randomized, controlled trial. J Clin Oncol 2012; 30: 1335-1342.
61. Jacobs SR, Jacobsen PB, Booth-Jones M, et al,. Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients. J Pain Symptom Manage 2007; 33: 13-23.
62. Crum RM, Anthony JC, Bassett SS, Folstein MF,. Population-based norms for the Mini-Mental State Examination by age and education level. J Am Med Assoc 1993; 269: 2386-2391.
63. Pocock SJ,. Clinical Trials: A Practical Approach. New York: John Wiley & Sons, 1983.
64. Jacobs SR, Jacobsen PB, Booth-Jones M, Wagner LI, Anasetti C,. Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients. J Pain Symptom Manage 2007; 33: 13-23.
65. Wefel JS, Lenzi R, Theriault R, et al,. 'Chemobrain' in breast carcinoma? A prologue. Cancer 2004; 101: 466-475.
66. Taillibert S, Voillery D, Bernard-Marty C,. Chemobrain: is systemic chemotherapy neurotoxic? Curr Opin Oncol 2007; 19: 623-627.
67. Wechsler D,. Wechsler Adult Intelligence Scale-III. San Antonio: The Psychological Corporation, 1997.
68. Benton AL, Hamsher K, Sivan AB,. Multilingual Aphasia Examination. Iowa City: AJA Associates, 1989.
69. Fletcher JM,. Memory for verbal and nonverbal stimuli in learning disabled subgroups: analysis by selective reminding. J Exp Child Psychol 1985; 40: 244-259.
70. Schmidt M,. Rey Auditory and Verbal Learning Test. A handbook. Los Angeles, CA: Western Psychological Services, 1996.
71. Radloff LS,. The CES-D scale: a new self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385-401.
72. Buysse DJ, Reynolds CF, Monk TH, Berman SR,. Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213.
73. Mendoza TR, Wang XS, Cleeland CS, et al,. The rapid assessment of fatigue severity in cancer patients. Cancer 1999; 85: 1186-1196.
74. Ware JE, Johnston SA, Davies-Avery A, et al,. Conceptualization and measurement of health for adults in the Health Insurance Study (Mental Health R-1987/3-HEW: 3). Santa Monica, CA: RAND Corporation, 1994.
75. Peterson AH, Fitchett GD, Brady MJ, Hernandez L, Cella D,. Measuring spiritual well-being in people with cancer: the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale (FACIT-Sp). Ann Behav Med 2002; 24: 49-58.
76. Cohen J,. Statistical Power Analysis for the Behavioral Sciences (2nd Ed.). Hillsdale, NJ: Lawrence Earlbaum Associates, 1988.
77. Rohling ML, Demakis GJ,. A meta-analysis of the neuropsychological effects of occupational exposure to mercury. Clin Neuropsychol 2006; 20: 108-132.
78. Cramp F, Daniel J,. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2008; 11: 1-38, CD006145.
79. Dietrich J, Monje M, Wefel J, Meyers C,. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 2008; 13: 1285-1295.